Information on the Marine Natural Products Gordon Research Conferences for 1996, 1998, 2000, 2002, 2004, 2006, 2008 and 2010 and 2012 can be reviewed at  http://www.grc.uri.edu/

Information on the Oceans and Human Health Gordon Research Conference  for 2008 and 2010 can be reviewed at  http://www.grc.uri.edu/

American Society for Experimental Pharmacology and Therapeutics Annual Meeting, San Diego, California, April 21-25, 2012.
 

Clinical pipeline of marine pharmaceuticals: The odyssey continues
San Diego Convention Center, Room 5A
3:00 pm – 5:30 pm
Sponsored by the Division for Drug Discovery, Development & Regulatory Affairs

Chairs: Keith B.Glaser, Abbott Laboratories and Alejandro M.S. Mayer, Midwestern University

Overview of the current marine clinical pharmaceutical pipeline.
Keith B.Glaser, Abbott Laboratories

Discovery of Eribulin mesylate (Halaven®): From marine natural product to FDA approved drug.
Melvin Yu, EISAI Pharmaceuticals

Discovery and development of the antibody drug conjugate, SGN-35 anti-CD30 conjugated to the dolastatin analog auristatin) in Phase III for cancer.
Peter Senter, Seattle Genetics

Discovery and development of the marine anticancer compounds Plinabulin (NPI-2358) in Phase II, and Marizomib (Salinosporamide A; NPI-0052) in Phase I.
G. Kenneth Lloyd, Nereus Pharmaceuticals, Inc.

Overview of the current preclinical marine pharmacology pipeline.
Alejandro M.S. Mayer, Midwestern University

Copyright © 2005-2011 Midwestern University. Last Rev. 9/26/2011. Direct questions or comments to Site Coordinator